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Abstract The activity of nuclear phosphoinositide 3-kinase C2L
(PI3K-C2L) was investigated in HL-60 cells induced to di¡er-
entiate along granulocytic or monocytic lineages. A signi¢cant
increase in the activity of immunoprecipitated PI3K-C2L was
observed in the nuclei and nuclear envelopes isolated from all-
trans-retinoic acid (ATRA)-di¡erentiated cells which was inhib-
ited by the presence of PI3K inhibitor LY 294002. High-perfor-
mance liquid chromatography analysis of inositol lipids showed
an increased incorporation of radiolabelled phosphate in both
PtdIns(3)P and PtdIns(3,4,5)P3 with no changes in the levels
of PtdIns(4)P, PtdIns(3,4)P2 and PtdIns(4,5)P2. Western blot
analysis of the PI3K-C2L immunoprecipitates with anti-P-Tyr
antibody revealed a signi¢cant increase in the level of the im-
munoreactive band corresponding to PI3K-C2L in the nuclei and
nuclear envelopes isolated from ATRA-di¡erentiated cells.
1 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Recent studies documented the nuclear production of the
3-phosphorylated phosphoinositides by the phosphoinositide
3-kinase (PI3K) in the nuclei of di¡erent cell types. PI3Ks
form a large family of enzymes that phosphorylate inositol
lipids at the D-3 position of the inositol ring and are divided
into three classes on the basis of their primary structure, reg-
ulation and in vitro lipid substrate speci¢city [1]. The most
studied are class I PI3Ks which produce mostly phosphatidyl-
inositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) in vivo. The
class IA enzymes consist of a 110 kDa catalytic subunit and
a 85 kDa adapter protein which links the enzyme to tyrosine
kinases in cell membranes; the class IB enzyme is composed
of a p110Q catalytic subunit and a p101 subunit regulated by
G-proteins. PI3Ks of class II generate phosphatidylinositol
3-phosphate (PtdIns(3)P) and phosphatidylinositol 3,4-bis-
phosphate (PtdIns(3,4)P2) and are large (170^210 kDa) pro-
teins which are distinguished by the presence of a PX domain
and C2 domains at their C-termini [1^3]. The human class III
enzyme is a homolog of yeast Vps34 gene product which
produces only PtdIns(3)P and regulates vesicle tra⁄cking
[4]. Immunocytochemical and biochemical analysis demon-
strated the presence of the p85K regulatory subunit in the
nuclei of rat and human cells [5^7], and the growth factor-
dependent nuclear translocation of the p110L catalytic subunit
in osteoblast-like cells [8]. A study based on the immunoloc-
alization of epitope-tagged p110Q in HepG2 cells reported that
PI3KQ translocates to the nucleus after serum stimulation [9],
and the presence of pertussis-toxin sensitive PI3K immuno-
logically related to PI3KQ was determined in the nuclei of
vascular smooth muscle cells [10]. Recent studies demon-
strated the activation of phosphoinositide 3-kinase C2L
(PI3K-C2L) and an increase in the level of PtdIns(3)P in the
membrane-depleted nuclei at the peak of rat liver regeneration
after partial hepatectomy [11], while PI3K-C2K was reported
to contain a nuclear localization sequence and to be associ-
ated with nuclear speckles [12].
Human promyelocytic leukemia HL-60 cells have been ex-
tensively studied as an experimental model of the molecular
mechanisms of leukemic and myelocytic di¡erentiation. HL-
60 cells di¡erentiate into monocyte-like cells following expo-
sure to interferon-Q (IFN-Q), and vitamin D3. All-trans-retino-
ic acid (ATRA) and dimethyl sulfoxide (DMSO) induce mat-
uration along neutrophilic pathways and phorbol 12-myristate
13-acetate (PMA) causes the cells to di¡erentiate into a mac-
rophage-like phenotype [13]. Although ATRA is generally
considered to act through the RAR/RXR nuclear receptors,
recent studies demonstrated that the ATRA-induced granulo-
cytic di¡erentiation of the HL-60 cell line is accompanied by a
speci¢c nuclear pattern of expression and activity of enzymes
related to the phosphoinositide signaling pathway [14,15]. The
presence of p85 protein and PI3K activity was found to be
tightly bound to the nuclear matrices and to increase during
the ATRA-induced granulocytic di¡erentiation [16], and the
inhibition of PI3K activity by wortmannin and its expression
by an antisense fragment of p85a prevented the di¡erentiation
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process [17]. The activation of nuclear PI3K of class IA is not
unique to the ATRA-mediated granulocytic di¡erentiation as
the activation of nuclear PI3K was demonstrated in vitamin
D3-treated HL-60 cells which were induced to di¡erentiate
along the monocytic lineage [18]. The mechanism of the
PI3K activation in the nucleus is incompletely understood,
but a possible role of Vav adapter was suggested in the acti-
vation of a nuclear class IA PI3K as an association of Vav
adapter molecule to PI3K was described in the nuclei of
ATRA-di¡erentiated HL-60 cells [19,20].
In the present study we investigated further the metabolism
of 3-phosphorylated phosphoinositides in the nuclei of HL-60
cells induced to di¡erentiate along granulocytic or monocytic
lineages. Our results show that the activity of immunopreci-
pitated PI3K-C2L and the level of PtdIns(3)P increase in the
nuclei and nuclear envelopes of ATRA-di¡erentiated HL-60
cells.
2. Materials and methods
2.1. Materials
Reagents were obtained from the following sources: IFN-Q, PMA,
DMSO, EGTA, EDTA, HEPES, Tris, dibutyryl-adenosine 3P, 5P-cy-
clic monophosphate (db cAMP), leupeptin, phenylmethylsulfonyl £u-
oride, phosphatidylserine (PtdSer), PtdIns, DNase I, RNase A, Triton
X-100, Naþ deoxycholate, protein A-Sepharose, sodium dodecyl sul-
fate (SDS), fetal bovine serum (FBS), and aprotinin from Sigma, St.
Louis, MO, USA; ATRA, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3),
LY 294002 from Calbiochem, Nottingham, UK; [Q-32P]ATP, and en-
hanced chemiluminescence kit from Amersham Pharmacia Biotech,
Amersham, UK; anti-P-Tyr antibody from Upstate Biotechnology,
Lake Placid, NY, USA; anti-epidermal growth factor receptor (anti-
EGFR) and anti-platelet-derived growth factor receptor (anti-
PDGFR) antibodies were from Santa Cruz Biotechnology, Santa
Cruz, CA, USA; FITC-conjugated monoclonal antibodies (MoAbs)
CD11b, murine IgG2a, murine IgG1 were purchased from Becton
Dickinson, Immunochemistry Systems, San Jose, CA, USA; MoAb
versus CD64, control murine IgG1 and rat F(ab)2-FITC against mu-
rine IgG from Serotec, Oxford, UK. All other chemicals were of
analytical grade.
2.2. Cell culture, cell di¡erentiation, and £ow cytometric analysis
HL-60 cells (ECCACC no. 88112501) were obtained from the Euro-
pean Collection of Animal Cell Cultures, PHLS, Porton, Salisbury,
UK. The cells were maintained in exponential growth in RPMI 1640
medium with 10% heat-inactivated FBS, 100 U/ml penicillin and 100
Wg/ml streptomycin in a 5% CO2 humidi¢ed atmosphere at 37‡C. For
cell di¡erentiation, cells were treated with one of the following agents:
1 WM ATRA (4 days), 500 nM 1,25(OH)2D3 (4 days), 2000 units/ml
IFN-Q (5 days), 1.25% DMSO (5 days), 500 WM db cAMP (5 days), or
500 nM PMA (3 days) at a cell density of 0.5U106/ml. At the indi-
cated times, cells were sampled and prepared for the £ow cytometric
analysis. The surface expression of CD11b, CD64/FcQRI or binding of
FITC-conjugated mouse IgG2a was determined by £ow cytometry as
previously described [21]. For each marker, a total of 10 000 events
was collected from the gated population and the £uorescence dis-
played on a single histogram with the cursor of the control samples
set to include up to 1.0% £uorescence in the positive region. The
results were collected as a percentage of events in the positive region
of the histogram.
2.3. Isolation of nuclei, postnuclear membranes and nuclear envelopes
and assessment of their purity
At the indicated time points, cells were sampled, washed three times
with cold phosphate-bu¡ered saline and resuspended in 50 mM Tris^
HCl, pH 7.4, 250 mM sucrose, 5 mM MgSO4 (STM bu¡er) contain-
ing 0.1 mM sodium metavanadate (NaVO3), 20 mM sodium £uoride,
10 Wg/ml leupeptin, 1 mM phenylmethylsulfonyl £uoride and 1% (v/v)
2-mercaptoethanol. After 5 min, the cells were lysed with 20 strokes of
a power-driven te£on pestle. The lysate was layered over a cushion of
2.1 M sucrose, 50 mM Tris^HCl, pH 7.4, 5 mM MgSO4 containing
inhibitors in the same concentration as the STM bu¡er. The samples
were then spun at 70 000Ug for 60 min in an SW 28.1 rotor. The
pellet at the bottom of the cushion was considered to be the nuclear
fraction [22]. Preparation of postnuclear membranes was achieved by
centrifugation of supernatant, which remained above the cushion after
the nuclear fraction had been obtained. The supernatant was diluted
in STM bu¡er to give a ¢nal concentration of 162 mM sucrose and
spun at 106 000Ug for 90 min at 4‡C in a Beckman SW 28.1 rotor.
The resultant pellet was considered to contain postnuclear membranes
[11].
Nuclear envelopes were isolated from puri¢ed nuclei as described
previously [22]. Brie£y, puri¢ed nuclei were resuspended in STM bu¡-
er containing 1% (v/v) 2-mercaptoethanol at 1U108 nuclei/ml and
incubated for 1 h at 4‡C with 100 Wg/ml DNase I and 100 Wg/ml
RNase A. After the incubation, the nuclei were sedimented at
800Ug for 10 min and resuspended in 50 mM Tris^HCl, pH 7.4, at
5U108 nuclei/ml; and four volumes of 50 mM Tris^HCl, pH 7.4,
containing 2 M NaCl and 1% (v/v) 2-mercaptoethanol were added
dropwise. After a 30 min incubation, nuclear envelopes were recov-
ered by sedimentation at 5000Ug for 30 min.
The activities of cytochrome oxidase and glucose-6-phosphatase
were determined according to Wakabayashi et al. [23] and Nordlie
and Arion [24], respectively, while the activity of 5P-nucleotidase was
measured as described by Burnside and Schneider [25].
2.4. Labeling of inositol lipids with [Q-32P]ATP
For the in vitro labeling of inositol lipids with [Q-32P]ATP nuclei or
nuclear envelopes (total protein 100 Wg) were resuspended in 90 Wl of
bu¡er containing 10 mM HEPES (pH 7.5), 5 mM MgCl2, 1.5 mM
KCl, 1 mM EGTA, and 0.25 M sucrose. The samples were preincu-
bated for 2 min at 30 ‡C to hydrolyze any remaining endogenous
ATP. Then 10 Wl of phosphorylation mixture (40 WCi of [Q-32P]ATP,
2 Wl of 5 mM non-radiolabeled ATP, made up to 10 Wl with the
above-mentioned bu¡er) was added. Incubation was carried out for
5 min at 30 ‡C and terminated by the addition of 1 ml of chloroform/
methanol (1:1). Lipids were extracted and deacylated, and the sepa-
ration of all the glycerophosphoinositides was achieved using a high-
performance liquid chromatography (HPLC) high resolution 5 WM
Partisphere SAX column (Whatman) with a discontinuous gradient
up to 1 M (NH4)2HPO4WH2PO4 (pH 3.8) exactly as described in the
previous study [11].
2.5. Immunoprecipitation of PI3K-C2L
PI3K-C2L isoform-discriminant polyclonal antisera against the ¢rst
331-amino acid portion of PI3K-C2L [2], expressed in Escherichia coli
as an amino-terminally fused glutathione S-transferase protein, were
raised in rabbits as described previously [11,26]. These antisera were
used for all immunoprecipitations and Western blots directed at
PI3K-C2L. Puri¢ed nuclei, postnuclear membranes, and nuclear enve-
lopes were resuspended in 0.5 ml of bu¡er containing 50 mM Tris (pH
7.6), 150 mM NaCl, 1% Triton X-100 (w/v), 0.5% Naþdeoxycholate
(w/v), 0.1% SDS (w/v), 2 mM phenylmethylsulfonyl £uoride, 1 Wg/ml
aprotinin, and 1 Wg/ml leupeptin and spun at 100 000Ug for 90 min at
4 ‡C. PI3K-C2L was immunoprecipitated overnight from 450 Wl of
supernatants with antibody and protein A-Sepharose. Immunopreci-
pitates were washed once with the above-mentioned bu¡er, then three
times with 5 mM HEPES/2 mM EDTA (pH 7.5) and then the phos-
phorylation assay was carried out as described above, except that
immunoprecipitates were resuspended in 40 Wl of bu¡er containing
10 mM HEPES (pH 7.5), 5 mM MgCl2, 1.5 mM KCl, 1 mM
EGTA, and 0.25 M sucrose and made up to 90 Wl with lipid vesicles
which consisted of 50 mM PtdIns and 100 mM PtdSer formed by
sonication. Incubation was terminated, lipids were extracted, deacy-
lated and separation of glycerophosphoinositide was achieved as de-
scribed above [11].
2.6. Western blot analysis
Proteins for electrophoresis were prepared so that the concentration
of each sample was 50 Wg/25 Wl of sample loading bu¡er [27], and
electrophoresis was carried out using a Bio-Rad Minigel apparatus at
an acrylamide concentration of 5% (v/v) or separation of proteins was
achieved on gradient gel 3^7% (v/v) when PI3K-C2L immunoprecipi-
tates were analyzed. After electrophoresis, the proteins were trans-
ferred to nitrocellulose using a Bio-Rad wet-blotting system. The
blot was blocked with a bu¡er containing 4% (w/v) dried milk,
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20 mM Tris, 140 mM NaCl, 0.05% (v/v) Tween 20. It was then probed
for 2 h with primary antibody (1:1000), washed with a blocking bu¡er
and incubated with the secondary antibody conjugated to horseradish
peroxidase. When PI3K-C2L immunoprecipitates were analyzed nitro-
cellulose was ¢rst probed with anti-PI3K-C2L antibody, then stripped
o¡ antibodies using bu¡er containing 62.5 mM Tris (pH 6.8), 2% SDS
(w/v) and 100 WM 2-mercaptoethanol for 30 min at 50 ‡C and re-
probed with anti-P-Tyr antibody. Visualization was carried out using
the ECL kit.
2.7. Statistical analysis
Results are shown as meansUS.E.M. For statistical analyses, Stu-
dent’s t-test for unpaired samples at a level of signi¢cance of 0.05 was
used.
3. Results
3.1. Assessment of purity of nuclei and postnuclear membranes
The purity of nuclei and postnuclear membranes was as-
sessed by measurement of activity of marker enzymes for mi-
crosomes (glucose-6-phosphatase), plasma membrane (5P-nu-
cleotidase) and mitochondria (cytochrome oxidase). In
isolated nuclei no speci¢c activity of 5P-nucleotidase and cy-
tochrome oxidase could be measured, while the speci¢c activ-
ity of glucose-6-phosphatase dropped from 0.324U 0.041
(Wmol Pi/mg protein per h) which was measured in original
homogenate to 0.035U 0.007 (Wmol Pi/mg protein per h) in
isolated nuclei, showing only residual contamination of nuclei
with microsomal marker enzyme similar to the level observed
in our previous studies [11,28], when liver nuclei were puri¢ed
even in the presence of strong detergents, suggesting that mi-
crosomal marker enzymes are present in the nuclear mem-
brane. On the other hand, when the speci¢c activity of the
above enzymes was measured in postnuclear membranes and
compared with speci¢c activity in original homogenate the
enrichment factors were 2.69 for glucose-6-phosphatase, 2.17
for 5P-nucleotidase and 2.49 for cytochrome oxidase, showing
that postnuclear membranes as well as nuclei were puri¢ed to
a satisfactory degree and could be used for further biochem-
ical studies.
3.2. The activity of PI3K-C2L increases in nuclei and nuclear
envelopes of ATRA-di¡erentiated HL-60 cells
To allow di¡erentiation along di¡erent pathways, HL-60
cells were incubated in the presence of one of the following
agents: 1 WM ATRA (4 days), 500 nM 1,25(OH)2D3 (4 days),
2000 units/ml IFN-Q (5 days), 1,25% vol/vol DMSO (5 days),
500 WM db cAMP (5 days), or 500 nM PMA (3 days). After
the incubation, an aliqout of cells was analyzed by £ow cyto-
metry to con¢rm the expression of surface markers, and the
rest of the sample was used to isolate nuclei and assayed for
the activity of immunoprecipitated PI3K-C2L. As shown in
Table 1, the activity of immunoprecipitated PI3K-C2L in nu-
clei isolated from ATRA-di¡erentiated HL-60 cells was sig-
ni¢cantly increased in comparison to the activity of the en-
zyme in nuclei isolated from cells treated with vehicle alone.
No increase in the level of immunoprecipitated PI3K-C2L
activity was observed in postnuclear membranes isolated
from ATRA-treated HL-60 cells. Although the presence of
DMSO, db cAMP, 1,25(OH)2D3, IFN-Q, or PMA induced
the expression of surface markers corresponding to di¡eren-
tiation, none of the agents tested induced any changes in the
level of PI3K-C2L activity in nuclei or postnuclear membranes
(Table 1). Highly puri¢ed nuclear envelopes were prepared
Table 1
The expression of surface markers and the activity of immunoprecipitated PI3K-C2L in nuclei and postnuclear membranes isolated from HL-60
cells induced to di¡erentiate with ATRA, 1,25(OH)2D3, IFN-Q, PMA, DMSO, and db cAMP
Surface markers (% positive cells) PI3K-C2L activity (dpm of PtdIns(3)P/100 Wg of protein)
CD11b CD 64 Nuclei Postnuclear membranes
Control 6.7U 3.5 1.4U 0.5 1679U 78 1758U 97
ATRA 58.6U 11.6* n.d. 4128U 172* 1802U 103
1,25(OH)2D3 62.3U 6.7* n.d. 1712U 105 1659U 115
IFN-Q n.d. 26.9U 1.4* 1755U 127 1664U 181
PMA 60.4U 5.2* n.d. 1662U 146 1759U 134
DMSO 52.2U 12.3* n.d. 1805U 128 1683U 142
db cAMP 47.5U 8.3* n.d. 1752U 161 1699U 155
HL-60 cells were incubated in the presence of one of the following agents: 1 WM ATRA (4 days), 500 nM 1,25(OH)2D3 (4 days), 2000 units/
ml IFN-Q (5 days), 500 nM PMA (3 days), 1,25% vol/vol DMSO (5 days), or 500 WM db cAMP (5 days). After the incubation, an aliquot of
cells was analyzed by £ow cytometry for the expression of surface markers. The rest of the sample was used to isolate nuclei and postnuclear
membranes and the immunoprecipitation of PI3K-C2L and the kinase assay using PtdIns as a substrate were performed as described in Section
2. The results are meansUS.E.M. for at least three di¡erent experiments, each performed in duplicate. *P6 0.05 (Student’s t-test) with respect
to the control. n.d., not determined.
Fig. 1. Activity of immunoprecipitated PI3K-C2L in postnuclear
membranes, nuclei and nuclear envelopes of either the control or
ATRA-treated HL-60 cells. Postnuclear membranes, nuclei and nu-
clear envelopes were isolated from HL-60 cells treated for 96 h with
either 1 WM ATRA (black bars), or vehicle alone (open bars). The
immunoprecipitation of PI3K-C2L and the kinase assay using
PtdIns as a substrate were performed as described in Section 2. The
e¡ect of the presence of LY 294002 (100 WM) during the phosphor-
ylation assay on the postnuclear membranes, nuclei and nuclear en-
velopes isolated from ATRA-treated cells is shown (gray bars). Re-
sults are meansUS.E.M. for three di¡erent experiments, each
performed in duplicate. *P6 0.05 (Student’s t-test) with respect to
the control.
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from ATRA-treated cells by sequential treatment of nuclei
with nucleases using the procedure which was previously
shown to remove nucleic acid, histones and some non-histone
proteins [22]. As shown in Fig. 1, a signi¢cant increase in the
level of immunoprecipitated PI3K-C2L activity was observed
in both nuclei and nuclear envelopes isolated from ATRA-
di¡erentiated HL-60 cells and when the phosphorylation as-
say was performed in the presence of PI-3 kinase inhibitor LY
294002 (100 WM) the activity of immunoprecipitated PI3K-
C2L was almost completely inhibited. More detailed analysis
of the sensitivity of the immunoprecipitable lipid kinase activ-
ity in the nuclear envelopes isolated from either control or
ATRA-treated HL-60 cells to the LY 294002 (Table 2) re-
vealed that IC50 in both control and ATRA-treated cells is
similar (9.6 WM versus 9.3 WM) and is comparable with that
which was observed when inhibitor was tested on puri¢ed
recombinant PI3K-C2L activity [3].
3.3. Phosphorylation of phosphoinositides in the nuclei and
nuclear envelopes isolated from ATRA-di¡erentiated
HL-60 cells
Nuclei and nuclear envelopes were isolated from either con-
trol or HL-60 cells treated with ATRA for 96 h and labeled
with [Q-32P]ATP for 5 min. As shown in Fig. 2, HPLC analysis
of deacylated phospholipids showed no di¡erence in the level
of incorporation of 32P into either phosphatidylinositol
4-phosphate (PtdIns(4)P) or phosphatidylinositol 4,5-bisphos-
phate (PtdIns(4,5)P2) in ATRA-di¡erentiated cells in compar-
ison to the control. No incorporation of 32P into PtdIns(3,4)P2
was detected. However, a signi¢cant increase was observed in
the incorporation of radioactivity in both PtdIns(3)P and
PtdIns(3,4,5)P3 in the nuclei and nuclear envelopes of
ATRA-di¡erentiated cells in comparison to the cells treated
with vehicle alone. Furthermore, this increased incorporation
was completely inhibited by the presence of 50 WM LY
294002. The increase in the production of PtdIns(3,4,5)P3 is
in agreement with previous studies, showing the activation of
class I PI3K in nuclei of ATRA-di¡erentiated cells [17]. How-
ever, the observed increase in radiolabeling of PtdIns(3)P in
the nuclei and nuclear envelopes of ATRA-di¡erentiated cells
is unlikely to be due to the activation of class I PI3K or
subsequent dephosphorylation of PtdIns(3,4,5)P3 as no incor-
poration of 32P into PtdIns(3,4)P2 could be detected. To fur-
ther distinguish between the activation of class I and class II
enzymes, the phosphorylation assay was carried out in the
presence of Ca2þ instead of Mg2þ, which would improve the
speci¢city of the assays towards that of the class II PI3K
enzymes as described by Arcaro et al. [3]. As shown in Table
3, no di¡erence in the incorporation rate of 32P into
PtdIns(3)P could be observed, while the incorporation rate
of 32P into PtdIns(3,4,5)P3 was reduced to about 20% of the
level observed when phosphorylation assay was carried out in
the presence of Mg2þ, further ruling out a possible involve-
ment of class I PI3K in the increase of nuclear PtdIns(3)P.
Since it is known that PI3K-C2L is able to phosphorylate
PtdIns, but not PtdIns(4)P in the presence of Ca2þ, while
some phosphorylation of PtdIns(4)P could be observed in
the presence of Mg2þ [3,29], in vitro substrate speci¢city for
immunoprecipitable PI3K-C2L was tested using Mg2þ for
phosphate transfer. As shown in Table 4, the basal level of
PtdIns phosphorylation is about four times higher than the
phosphorylation of PtdIns(4)P and this proportion increases
to about six times in the nuclei and nuclear envelopes har-
vested after stimulation of HL-60 cells with ATRA, showing
that there is a strong preference for PtdIns over PtdIns(4)P as
a substrate in both basal and stimulated condition, which
could be completely inhibited by 100 WM LY 294002 as has
been demonstrated for puri¢ed recombinant enzyme [3]. Fur-
thermore, no phosphorylation of PtdIns(4,5)P2 could be ob-
served, showing that we were able to immunoprecipitate only
class II PI3K, since the enzyme activity in immunoprecipitates
failed to phosphorylate this substrate which should get phos-
phorylated if any class I PI3K co-immunoprecipitated with
class II PI3K. Moreover, as the PI3K activity in immunopre-
cipitates was unable to phosphorylate PtdIns(4,5)P2 but could
phosphorylate PtdIns(4)P into PtdIns(3,4)P2, the possible role
Table 2
E¡ect of LY 294002 on immunoprecipitable PI3K-C2L activity in
the nuclear envelopes isolated from either control or ATRA-treated
HL-60 cells
Concentration of LY
294002 (WM)
Control ATRA
0 2109U145 5337U 272
1 2004U132 5128U 225
5 1796U121 3722U 207*
10 1002U88* 2522U 181*
50 593U71* 1722U 103*
100 150U37* 322U 72*
Nuclear envelopes were isolated from HL-60 cells treated for 96 h
with either 1 WM ATRA or vehicle alone, and the immunoprecipita-
tion of PI3K-C2L and kinase assay was carried out using PtdIns as
substrates as described in Section 2. The results are meansUS.E.M.
for three di¡erent experiments, each performed in duplicate.
*P6 0.05 (Student’s t-test) with respect to the controls.
Table 3
Incorporation of 32P into PtdIns(3)P and PtdIns(3,4,5)P3 in the nuclei and nuclear envelopes isolated from either the control or ATRA-treated
HL-60 cells
Incorporation of 32P into PtdIns(3)P
(dpm/100 Wg of protein)
Incorporation of 32P into PtdIns(3,4,5)P3
(dpm/100 Wg of protein)
Mg2þ Ca2þ Mg2þ Ca2þ
Control nuclei 311U 56 298U61 476U 78 86U 18
ATRA nuclei 1078U 105* 1111U102* 1292U 105* 196U 37*
Control nuclear envelopes 372U 69 356U70 455U 55* 91U 16
ATRA nuclear envelopes 1242U 172* 1311U128* 1463U 147* 227U 29*
Nuclei and nuclear envelopes were isolated from HL-60 cells treated for 96 h with either 1 WM ATRA or vehicle alone. Lipids in the nuclei
and nuclear envelopes were radiolabeled using [Q-32P]ATP, and the separation of glycerophosphoinositides was achieved as described in Section
2. When phosphorylation assay was carried out in the presence of Ca2þ, 5 mM CaCl2 was added to the bu¡er instead of 5 mM MgCl2 and
1 mM EGTA was replaced by 1 mM EDTA. The results are meansUS.E.M. for three di¡erent experiments, each performed in duplicate.
*P6 0.05 (Student’s t-test) with respect to the control.
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of class III activity could be ruled out. Knowing that in the
nuclei the concentration of PtdIns is about 15 times higher
than PtdIns(4)P [28,30], and that in in vitro conditions with
equimolar concentration of substrates, PtdIns(4)P could be
phosphorylated only in the presence of Mg2þ with substan-
tially less e⁄ciency than PtdIns [3,29], it seems obvious
that in vivo PI3K-C2L phosphorylates PtdIns to produce
PtdIns(3)P.
3.4. Tyrosine phosphorylation of PI3K-C2L isolated from
nuclei and nuclear envelopes of ATRA-di¡erentiated
HL-60 cells
In postnuclear membranes, nuclei and nuclear envelopes
isolated from both control and ATRA-treated cells, Western
blot analysis revealed the presence of a PI3K-C2L immunore-
active band of 180 kDa (Fig. 3). No changes in the amount of
PI3K-C2L protein were detected in either nuclei or nuclear
envelopes isolated from ATRA-treated cells in comparison
to the control. In the next experiment (Fig. 4), PI3K-C2L
was ¢rst immunoprecipitated from postnuclear membranes,
nuclei and nuclear envelopes of the control and ATRA-
treated cells using anti-PI3K-C2L antibody, then subjected
to gradient gel SDS^PAGE and probed ¢rst with anti-PI3K-
C2L antibody (panel A), which revealed two bands of slightly
di¡erent molecular weights, showing that gel-shift of immu-
noreactive band towards higher molecular weight has oc-
curred in nuclei and nuclear envelopes of ATRA-treated cells.
Nitrocellulose membrane was then stripped o¡ anti-PI3K-C2L
antibody and probed with anti-P-Tyr antibody, which re-
vealed a single immunoreactive band (panel B), which corre-
sponds to a higher molecular weight band found in panel A,
with signi¢cant increase in the level of immunoreactive band
found in the nuclei and nuclear envelopes isolated from
ATRA-di¡erentiated cells, suggesting that in the nuclei and
nuclear envelopes isolated from ATRA-di¡erentiated cells
PI3K-C2L is subjected to tyrosine phosphorylation which
causes gel-shift of the enzyme. Moreover, since it is known
that upon cell stimulation PI3K-C2L binds to tyrosine kinase
receptors such as EGFR and PDGFR [29], in a separate ex-
periment PI3K-C2L was ¢rst immunoprecipitated using anti-
Table 4
Substrate speci¢city of immunoprecipitable PI3K-C2L activity in the nuclei and nuclear envelopes isolated from either control or ATRA-treated
HL-60 cells and the e¡ect of LY 294002 (100 WM) during phosphorylation assay on the nuclei and nuclear envelopes isolated from ATRA-
treated cells
Treatment PtdIns(3)P
(dpm/100 Wg of protein)
PtdIns(3,4)P2
(dpm/100 Wg of protein)
PtdIns(3,4,5)P3
(dpm/100 Wg of protein)
Nuclei Nuclear envelopes Nuclei Nuclear envelopes Nuclei Nuclear envelopes
None 1678U64 2109U 133 388U51 433U 33 n.d. n.d.
ATRA 4222U155* 5337U 272* 715U77* 822U 59* n.d. n.d.
ATRA+LY 301U54* 322U 72* n.d. n.d. n.d. n.d.
Nuclei and nuclear envelopes were isolated from HL-60 cells treated for 96 h with either 1 WM ATRA, or vehicle alone, and the immunopre-
cipitation of PI3K-C2L and kinase assays were carried out using PtdIns, PtdIns(4)P or PtdIns(4,5)P2 as substrates as described in Section 2.
The results are meansUS.E.M. for three di¡erent experiments, each performed in duplicate. *P6 0.05 (Student’s t-test) with respect to the con-
trols. n.d., not detected.
Fig. 2. Incorporation of 32P into PtdIns(3)P, PtdIns(4)P,
PtdIns(4,5)P2, and PtdIns(3,4,5)P3 in the nuclei (A) and nuclear en-
velopes (B) isolated from either the control or ATRA-treated HL-60
cells. Nuclei (A) and nuclear envelopes (B) were isolated from HL-
60 cells treated for 96 h with either 1 WM ATRA (black bars), or
vehicle alone (open bars). Lipids in the nuclei and nuclear envelopes
were radiolabeled using [Q-32P]ATP, and the separation of glycero-
phosphoinositides was achieved as described in Section 2. The e¡ect
of the presence of LY 294002 (50 WM) during the phosphorylation
assay on the nuclei and nuclear envelopes isolated from ATRA-
treated cells is shown (gray bars). The results are means US.E.M.
for three di¡erent experiments, each performed in duplicate.
*P6 0.05 (Student’s t-test) with respect to the control.
Fig. 3. Western blot analysis of PI3K-C2L in subcellular fractions
of either the control or ATRA-treated HL-60 cells. Postnuclear
membranes (PNM), nuclei (N) and nuclear envelopes (NE) were iso-
lated from either the control (3) or ATRA-treated (+) HL-60 cells.
Protein (50 Wg) was subjected to SDS^PAGE, transferred to nitro-
cellulose, and probed with anti-PI3K-C2L antibody. The position of
the molecular mass marker for K2-macroglobulin (180 kDa) is indi-
cated on the right by the arrow.
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PI3K-C2L antibody from nuclei and nuclear envelopes of the
control and ATRA-treated cells and then subjected to West-
ern blot analysis using either anti-PDGFR antibody or anti-
EGFR antibody. As no immunoreactive band could be de-
tected (results not shown) this corroborates our conclusion
that the tyrosine phosphorylated protein seen in Fig. 4 is in-
deed PI3K-C2L and not one of the tyrosine kinase receptors
such as EGFR or PDGFR.
4. Discussion
In contrast to class I PI3Ks, which have been extensively
studied in response to di¡erent agonists in both the cell
membrane and nuclei, little is known about the physiological
role and mode of activation of PI3K-C2L. The cloning of the
enzyme revealed its relatively high molecular mass (180 kDa),
the presence of C2 and PX homology region at C-termini, an
N-terminal extension and no binding of adapter proteins sim-
ilar to those described for class I [2,3]. In vitro studies showed
that the enzyme preferentially phosphorylates PtdIns, or, with
much lower a⁄nity, PtdIns(4)P but not PtdIns(4,5)P2, and is
sensitive to the inhibitory e¡ect of wortmannin and LY
294002 [3]. The activation of PI3K-C2L has been described
in response to ¢brinogen-activated integrin receptors in plate-
lets [26], PDGF and EGF-mediated receptor activation in ep-
ithelial cell and ¢broblasts [29,31], but also in membrane-de-
pleted rat liver nuclei at the peak of compensatory liver
growth [11]. A possible proteolytic activation of the enzyme
was suggested, as data showed that the lipid kinase activity of
PI3K-C2L increased after the deletion of the C2 domain [3],
and the following studies done on ¢brinogen-activated plate-
lets [26] or regenerating liver nuclei [11] showed that the acti-
vation of the enzyme is associated with a 18 kDa gel-shift
which could be mimicked by the addition of calpain and pre-
vented in the presence of calpain-inhibitor, calpeptin. Another
mode of PI3K-C2L activation has recently been suggested as
the interaction between the enzyme and the activated EGF
receptor was shown to depend on the binding of Grb2 adapter
molecule to the proline-rich motifs within the N-termini of
PI3K-C2L [31]. The results of the present study demonstrated
a signi¢cant increase in the activity of PI3K-C2L immunopre-
cipitated from the nuclei and nuclear envelopes of ATRA-
di¡erentiated HL-60 cells, together with increased level of ty-
rosine phosphorylation of the enzyme and a parallel increase
in the level of nuclear PtdIns(3)P, suggesting that the enzyme
may be activated by tyrosine phosphorylation.
Class I PI3K activity responsible for the production of
PtdIns(3,4,5)P3 in the membrane-depleted nuclei of ATRA-
di¡erentiated cells was detected to be tightly bound to nuclear
matrices isolated by nuclease treatment and high salt extrac-
tion and to correspond to an increased level of nuclear p85
protein in immunolocalization studies [16]. Although the
probing of the p85 immunoprecipitates with anti-Tyr antibod-
ies showed that p85 itself was not phosphorylated, two bands
of high molecular weights were tyrosine-phosphorylated and
co-migrated with Vav and phospholipase C-Q, respectively
[19]. On the other hand, in erythropoietin-induced erythroid
di¡erentiation of K562 cells the p85 regulatory subunit was
highly phosphorylated on tyrosine residues when translocated
to the nucleus, causing an increase in intranuclear synthesis of
PtdIns(3,4,5)P3 [32]. In our study, no additional phosphopro-
teins were identi¢ed in PI3K-C2L immunoprecipitates, sug-
gesting that the mechanism of the activation of the nuclear
PI3K-C2L does not involve a di¡erentiation-induced associa-
tion with adapter molecules. Another di¡erence between the
activation of class I enzymes and PI3K-C2L in the nuclei of
HL-60 cells is the absence of the increase in the activity of
PI3K-C2L in the nuclei of vitamin D3-di¡erentiated cells. The
activation of class I enzymes is detected in the nuclei of cells
induced to di¡erentiate along monocytic lineage by the treat-
ment with 1,25(OH)2D3 [18], but the activity of PI3K-C2L
remains unchanged in the nuclei of cells induced to di¡eren-
tiate not only in the presence of vitamin D3, but also after the
treatment with either IFN-Q or PMA, which increase the ex-
pression of markers of mature monocytes or macrophages. It
is unknown what is the possible role of the activation of
PI3K-C2L in the nuclei of ATRA-di¡erentiated cells, but
the activity does not seem to correspond to granulocytic lin-
eage commitment as no increase was observed in the nuclei of
cells induced to di¡erentiate by the treatment with DMSO or
db cAMP.
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